University Hospital Halle (Saale) Trials

University Hospital Halle (Saale)	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Weber, Thomas

AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting

482

Europe

Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)

Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH

Multiple Myeloma

03/28

03/33

NCT03474744 / 2017-003150-16: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

Active, not recruiting

Europe

Copanlisib, Aliqopa, Rituximab, Truxima

Christian Buske, University of Ulm, Optimapharm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Celltrion Healthcare Co., LTD, Bayer

Marginal Zone Lymphoma

06/24

12/29

R-Pola-Glo, NCT05798156: Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Recruiting

125

Europe

Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche

Lymphoma, Large B-Cell, Diffuse

04/25

09/28

NCT06368518: Austrian Hypertrophic Cardiomyopathy Registry

Recruiting

N/A

1000

Europe

Medical University of Graz

Hypertrophic Cardiomyopathy

03/44

TOGETHER, NCT06761235: Knowledge of Vascular Age Contributes to Improve the Collaboration Between Community Pharmacies and Primary Health Care Physicians in Reducing Blood Pressure in Hypertensive Patients.

Not yet recruiting

N/A

1246

Europe

Standard BP intervention, Ambulatory blood pressure monitoring to diagnose hypertension and educational sessions to empower hypertensive patients, EVA intervention, Ambulatory blood pressure monitoring to diagnose hypertension plus estimated vascular age by brachial oscillometry and educational sessions to empower hypertensive patients

Enrique Rodilla, Health Research Fund of ISCIII Spain, AIT Austrian Institute of Technology GmbH, Institut et Haute Ecole de la SantÃ© la Source, Instituto PolitÃ©cnico de Coimbra, European Union

Hypertension and Cardiovascular Risk Factors

11/26

12/26

MÃ¼ller, Lutz P

GRAPPA, NCT05153226: GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG

Active, not recruiting

640

Europe

Cyclophosphamide, all brands, ATG, ATG Grafalon

DKMS gemeinnützige GmbH

Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation, AML, MDS, MDS/MPN, CMML

06/25

12/26

AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting

482

Europe

Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH

Multiple Myeloma

03/28

03/33

HAMLET, NCT03275636 / 2015-005399-12: Haploidentical Donor vs mMUD in Hematological Malignancies

Completed

2/3

Europe

Peripheral blood stem cells, PBSC

DKMS gemeinnützige GmbH

AML, ALL, MDS

04/24

NCT03188874: Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

Recruiting

N/A

15000

Europe

Technische Universität Dresden

Acute Myeloid Leukemia (AML)

09/30

Ronellenfitsch, Ulrich

TATRA, NCT06414031: Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery

Recruiting

850

Europe

Tranexamic Acid, Tranexamsäure Carinopharm 100mg/ml, Placebo, Isotone Kochsalz-Lösung 0,9% Infusionslösung

Ulrich Ronellenfitsch, MD, German Federal Ministry of Education and Research, Coordinating Centre for Clinical Trials Halle

Surgical Blood Loss, Transfusion-dependent Anemia, Abdomen Disease

11/25

NCT04246684: Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Active, not recruiting

702

Europe

Oxaliplatin, 85 mg/m2, Control arm, 5FU; 2400 mg/m2, 5-FU, control arm, 5FU, 250 mg/m2, Experimental arm: 5-FU, 5FU, 2400 mg/m2, experimental arm, Oxaliplatin 50 mg/m2, Experimental arm, Folinic Acid, 400 mg/m2, Folinic Acid, Radiotherapy control, 5x5 Gy: 25 Gy, Capecitabine, 1000 mg/m2, Capecitabine, Oxaliplatin 85 mg/m2, radiotherapy experimental, 30 x 1,8 Gy: 54 Gy, Capecitabine, 825 mg/m2, Oxaliplatin, 130 mg/m2, Oxaliplatin

Prof. Dr. med. Claus Rödel

Rectal Cancer Stage III

09/23

09/28

PRESTO, NCT05713838: Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Recruiting

Europe

Durvalumab, IMFINZI, FLOT, mFOLFOX-6, Radiotherapy

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Esophagus Adenocarcinoma

12/25

12/28

HOLIPANC, NCT04617457 / 2019-002734-37: Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas

Recruiting

150

Europe

nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA), nal-irinotecan (nal-iri), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA), ONIVYDE TM

University of Cologne, Servier

Pancreatic Cancer, Metastasis, Surgery, Oligometastatic Disease

12/24

09/25

PREVADER, NCT04136769: Preoperative/Neoadjuvant Therapy and Vascular Debranching Followed by Resection for Locally Advanced Pancreatic Cancer

Terminated

N/A

Europe

Visceral Debranching, Revascularisation of visceral arteries

Ulrich Ronellenfitsch, MD

Pancreas Cancer

12/24

Kleeff, Jörg

PREVADER, NCT04136769: Preoperative/Neoadjuvant Therapy and Vascular Debranching Followed by Resection for Locally Advanced Pancreatic Cancer

Terminated

N/A

Europe

Visceral Debranching, Revascularisation of visceral arteries

Ulrich Ronellenfitsch, MD

Pancreas Cancer

12/24

Theurich, Sebastian

AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting

482

Europe

Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH

Multiple Myeloma

03/28

03/33

Svatko, zhanna

NCT04927156: Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform

Recruiting

N/A

10000

Europe

BALT medical devices

Balt Extrusion

Intracranial Aneurysm, Brain Arterial Disease, Acute Ischemic Stroke, Peripheral Vascular Diseases, AVM - Cerebral Arteriovenous Malformation, AVM

06/41

10/41

Blank, Valentin

LivSPECTRUS, NCT06317181: Assessment of Liver Diseases Using a Deep-Learning Approach Based on Ultrasound RF-Data

Recruiting

N/A

200

Europe

Collection of elastography data, Collection of ultrasonic raw data

Technische Universität Dresden, University Hospital Dresden, University of Leipzig

Artificial Intelligence, Ultrasonography, Elasticity Imaging Techniques, Liver Diseases, Metastasis to Liver

06/25

12/25



	Diseases Companies Products Productz Mechanisms of Action Sites